Timing of the administration of suramin treatment after muscle injury

It has been reported that suramin treatment can improve muscle healing; however, details about optimizing the dosing requirements remain unclear. The purpose of this study was to determine the optimal timing of suramin administration and investigate the effects it had on the expression of myostatin, follistatin, and muscle vascularity after muscle injury.

[1]  F. Ambrosio,et al.  Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  J. Rousseau,et al.  Overexpression of Follistatin in Human Myoblasts Increases Their Proliferation and Differentiation, and Improves the Graft Success in SCID Mice , 2009, Cell transplantation.

[3]  Philip Bao,et al.  The role of vascular endothelial growth factor in wound healing. , 2009, The Journal of surgical research.

[4]  T. Haas,et al.  Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. , 2009, Current pharmaceutical design.

[5]  Freddie H. Fu,et al.  Improved Muscle Healing after Contusion Injury by the Inhibitory Effect of Suramin on Myostatin, a Negative Regulator of Muscle Growth , 2008, The American journal of sports medicine.

[6]  Yong Li,et al.  Angiotensin II Receptor Blockade Administered after Injury Improves Muscle Regeneration and Decreases Fibrosis in Normal Skeletal Muscle , 2008, The American journal of sports medicine.

[7]  K. Tsuchida,et al.  Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  E. Breen.  VEGF in biological control , 2007, Journal of cellular biochemistry.

[9]  F. Ambrosio,et al.  Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. , 2007, The Journal of biological chemistry.

[10]  M. Rudnicki,et al.  Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Buhr,et al.  Suramin Inhibits Not Only Tumor Growth and Metastasis but Also Angiogenesis in Experimental Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.

[12]  Freddie H. Fu,et al.  The Effect of Relaxin Treatment on Skeletal Muscle Injuries , 2005, The American journal of sports medicine.

[13]  L. Mcleay,et al.  Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice , 2005, Journal of Cell Science.

[14]  L. Bünger,et al.  Effects of the Compact Mutant Myostatin Allele Mstn Cmpt-dl1Abc Introgressed into a High Growth Mouse Line on Skeletal Muscle Cellularity , 2005, Journal of Muscle Research & Cell Motility.

[15]  Yong Li,et al.  The Use of Suramin, an Antifibrotic Agent, to Improve Muscle Recovery after Strain Injury , 2005, The American journal of sports medicine.

[16]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[17]  K. Patel,et al.  Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. , 2004, Developmental biology.

[18]  Yong Li,et al.  Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. , 2004, The American journal of pathology.

[19]  F. Martinez,et al.  Mechanisms of pulmonary fibrosis. , 2004, Annual review of medicine.

[20]  R. Bray,et al.  Correlation of healing capacity with vascular response in the anterior cruciate and medial collateral ligaments of the rabbit , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  Yong Li,et al.  Gamma interferon as an antifibrosis agent in skeletal muscle , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  Freddie H. Fu,et al.  Antifibrotic effects of suramin in injured skeletal muscle after laceration. , 2003, Journal of applied physiology.

[23]  S. Phan.  The myofibroblast in pulmonary fibrosis. , 2002, Chest.

[24]  Yong Li,et al.  Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. , 2002, The American journal of pathology.

[25]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[26]  Yong Li,et al.  Muscle injuries and repair: current trends in research. , 2002, The Journal of bone and joint surgery. American volume.

[27]  Johnny Huard,et al.  The Use of an Antifibrosis Agent to Improve Muscle Recovery after Laceration * , 2001, The American journal of sports medicine.

[28]  H Kalimo,et al.  Muscle strain injuries. , 2000, Current opinion in rheumatology.

[29]  Freddie H. Fu,et al.  Development of approaches to improve the healing following muscle contusion. , 1998, Cell transplantation.

[30]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[31]  A. Fainsod,et al.  The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4 , 1997, Mechanisms of Development.

[32]  W. Garrett.  Muscle Strain Injuries , 1996, The American journal of sports medicine.

[33]  V. Hombach,et al.  Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. , 1996, Journal of molecular and cellular cardiology.

[34]  K. Harding,et al.  Cutaneous wound healing: a current perspective. , 1995, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[35]  P. Schofield,et al.  Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. , 1995, Anticancer research.

[36]  H. Lorenz,et al.  A model of scarless human fetal wound repair is deficient in transforming growth factor beta. , 1995, Journal of pediatric surgery.

[37]  M. Panjabi,et al.  A Muscle Contusion Injury Model , 1994, The American journal of sports medicine.

[38]  C. Stein,et al.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.

[39]  G. D. Phillips,et al.  An Angiogenic Extract from Skeletal Muscle Stimulates Monocyte and Endothelial Cell Chemotaxis In Vitro , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[40]  M. Järvinen,et al.  Healing of skeletal muscle injury: an ultrastructural and immunohistochemical study. , 1991, Medicine and science in sports and exercise.

[41]  W. Garrett.  Muscle strain injuries: clinical and basic aspects. , 1990, Medicine and science in sports and exercise.

[42]  A. Rostami,et al.  Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. , 1990, Immunology.

[43]  M. Fardeau,et al.  Regeneration of skeletal muscle fibers from autologous satellite cells multiplied in vitro. An experimental model for testing cultured cell myogenicity , 1989, Muscle & nerve.

[44]  B L Freeman,et al.  A chronicle of injuries of an American intercollegiate football team , 1981, The American journal of sports medicine.

[45]  M. Grounds.  Towards understanding skeletal muscle regeneration. , 1991, Pathology, research and practice.

[46]  J. Faulkner,et al.  The regeneration of skeletal muscle fibers following injury: a review. , 1983, Medicine and science in sports and exercise.

[47]  D. Fischman.  The synthesis and assembly of myofibrils in embryonic muscle. , 1970, Current topics in developmental biology.